Asked by: Jodie Gosling (Labour - Nuneaton)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, whether (a) physiotherapists, (b) occupational therapists, (c) nurses, (d) pharmacists, and (e) other healthcare professionals who have been eligible to issue fit notes since July 2022 will be issuing fit notes as part of the new fit note pilot schemes.
Answered by Diana Johnson - Minister of State (Department for Work and Pensions)
All healthcare professionals currently eligible to issue fit notes will continue to be able to do so. The Government is not bringing forward any changes to fit note legislation as part of the fit note reform pilots.
The four fit note pilots will test a voluntary service in which new Community Work and Health Teams work alongside patients and their employers to develop personalised workability plans to support people to remain in work or to return to work sustainably. All four pilots include, within the make-up of the team workforce, healthcare professionals eligible to issue fit notes where required.
Asked by: Jodie Gosling (Labour - Nuneaton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the NHS's document entitled Neighbourhood health centre guidance for regions and integrated care boards published on 16 April 2026, whether physiotherapists are included in the community health team.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Neighbourhood health centres (NHCs) will bring together general practice (GP) with a mix of community, local authority, adult social care, and civil society services, allowing staff to deliver more coordinated and effective care for better patient outcomes and experiences. As set out in the Neighbourhood Health Centre guidance for regions and integrated care boards, NHCs will at minimum be expected to include an on-site GP, community health, and integrated neighbourhood teams (INTs). These INTs bring together different professions and partners to work side by side to support people.
The range of services available within NHCs will reflect the needs of the local population, meaning provision may vary between areas depending on local health priorities and community demand. The mix of services and professions, including whether physiotherapy forms a part of the community health team in a given centre, will be decided locally by integrated care boards and regions.
We will publish our 10 Year Workforce plan to ensure that the National Health Service has the right people, in the right places, with the right skills to deliver the care patients needs when they need it.
Asked by: Jodie Gosling (Labour - Nuneaton)
Question to the Department for Energy Security & Net Zero:
To ask the Secretary of State for Energy Security and Net Zero, what recent steps his Department has taken to rectify poor quality works undertaken as part of the Energy Company Obligation 4 scheme.
Answered by Martin McCluskey - Parliamentary Under Secretary of State (Department for Energy Security and Net Zero)
We are offering an audit to all households that received external wall insulation (EWI) measures under ECO4 and GBIS schemes. Since this became fully operational in January, over 9,000 properties have been contacted, with over 3,000 audits completed.
The original installer is responsible for remediating issues with their work and the costs involved. Where an installer ceases to trade or fails to rectify issues, SWI measures have a guarantee covering up to £20k.
Remediation is already taking place to address substandard and unsafe work, and over half of the issues identified with solid wall insulation to date have been fixed.
Asked by: Jodie Gosling (Labour - Nuneaton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has considered exempting information on how to use adrenaline devices from restrictions only allowing medical professionals to access information about prescription medicines.
Answered by Preet Kaur Gill - Parliamentary Under-Secretary (Department of Health and Social Care)
Following the approval of an adrenaline nasal spray by the Medicines and Healthcare products Regulatory Agency (MHRA) in July 2025, the Government is considering whether any amendments to Schedule 17 of the Human Medicines Regulations 2012 are appropriate. Any changes to access arrangements would represent an amendment to the current regulatory framework and would require consideration of patient safety and appropriate clinical use. Should changes be proposed, a public consultation would be undertaken.
The National Institute of Health and Care Excellence (NICE) has been notified of the considerations being made by the Department in this area. NICE is not currently considering producing guidance on EURneffy. NICE will continue to monitor new evidence on this topic, in line with its usual processes. NICE has met with the National Institute for Health and Care Research which has agreed to explore whether research on this topic would be feasible and, if so, what research programme it might be suited to.
There are no restrictions on accessing information on how to use adrenaline devices, whether by a medical professional or member of the public. Guidance from the MHRA on their website and on YouTube includes information on the correct use of adrenaline auto-injectors and what to do in an emergency, with further information available at the following two links:
https://www.youtube.com/watch?v=4vNR5N1-iBw
The manufacturers of adrenaline devices also provide a range of training materials freely available to the public, including training devices without medication, guides on instructions for use, and video demonstrations.
Asked by: Jodie Gosling (Labour - Nuneaton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has considered the potential merits of legislating to allow for community access to adrenaline.
Answered by Preet Kaur Gill - Parliamentary Under-Secretary (Department of Health and Social Care)
Following the approval of an adrenaline nasal spray by the Medicines and Healthcare products Regulatory Agency (MHRA) in July 2025, the Government is considering whether any amendments to Schedule 17 of the Human Medicines Regulations 2012 are appropriate. Any changes to access arrangements would represent an amendment to the current regulatory framework and would require consideration of patient safety and appropriate clinical use. Should changes be proposed, a public consultation would be undertaken.
The National Institute of Health and Care Excellence (NICE) has been notified of the considerations being made by the Department in this area. NICE is not currently considering producing guidance on EURneffy. NICE will continue to monitor new evidence on this topic, in line with its usual processes. NICE has met with the National Institute for Health and Care Research which has agreed to explore whether research on this topic would be feasible and, if so, what research programme it might be suited to.
There are no restrictions on accessing information on how to use adrenaline devices, whether by a medical professional or member of the public. Guidance from the MHRA on their website and on YouTube includes information on the correct use of adrenaline auto-injectors and what to do in an emergency, with further information available at the following two links:
https://www.youtube.com/watch?v=4vNR5N1-iBw
The manufacturers of adrenaline devices also provide a range of training materials freely available to the public, including training devices without medication, guides on instructions for use, and video demonstrations.
Asked by: Jodie Gosling (Labour - Nuneaton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if his Department will update Schedule 17 of the Human Medicines Regulations 2012 to allow for use of adrenaline nasal sprays.
Answered by Preet Kaur Gill - Parliamentary Under-Secretary (Department of Health and Social Care)
Following the approval of an adrenaline nasal spray by the Medicines and Healthcare products Regulatory Agency (MHRA) in July 2025, the Government is considering whether any amendments to Schedule 17 of the Human Medicines Regulations 2012 are appropriate. Any changes to access arrangements would represent an amendment to the current regulatory framework and would require consideration of patient safety and appropriate clinical use. Should changes be proposed, a public consultation would be undertaken.
The National Institute of Health and Care Excellence (NICE) has been notified of the considerations being made by the Department in this area. NICE is not currently considering producing guidance on EURneffy. NICE will continue to monitor new evidence on this topic, in line with its usual processes. NICE has met with the National Institute for Health and Care Research which has agreed to explore whether research on this topic would be feasible and, if so, what research programme it might be suited to.
There are no restrictions on accessing information on how to use adrenaline devices, whether by a medical professional or member of the public. Guidance from the MHRA on their website and on YouTube includes information on the correct use of adrenaline auto-injectors and what to do in an emergency, with further information available at the following two links:
https://www.youtube.com/watch?v=4vNR5N1-iBw
The manufacturers of adrenaline devices also provide a range of training materials freely available to the public, including training devices without medication, guides on instructions for use, and video demonstrations.
Asked by: Jodie Gosling (Labour - Nuneaton)
Question to the Foreign, Commonwealth & Development Office:
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what steps her Department is taking with international partners to help tackle alleged human rights violations against members of the Baháʼí community in Iran, including reports of mistreatment, torture and lack of access to adequate medical treatment for those detained as prisoners.
Answered by Hamish Falconer - Parliamentary Under-Secretary (Foreign, Commonwealth and Development Office)
I refer the Hon Member to the answer provided on 19 May in response to Question 611.
Asked by: Jodie Gosling (Labour - Nuneaton)
Question to the Ministry of Defence:
To ask the Secretary of State for Defence, what assessment he has made of the adequacy of current entry requirements for the armed forces reserve; and whether his Department plans to review entry requirements for the armed forces reserves.
Answered by Louise Sandher-Jones - Parliamentary Under-Secretary (Ministry of Defence)
The Ministry of Defence (MOD) continually assesses the entry requirements for Reserve recruitment and is actively streamlining joining processes, along with many other aspects of the Reserves, to ensure they support national resilience.
This Government has taken several actions to set conditions of growth and utility of the Reserves workforce such as the Pan Defence Skills Framework, the Armed Forces Recruitment Service and the ZigZag career pilot. Through the Armed Forces Bill 2026, Reserves measures seek to significantly expand the UK's Strategic Reserve and modernise mobilisation.
The Strategic Defence Review has set a path for the next decade and beyond to transform Defence and it will end the hollowing out of our Armed Forces. We are committed to the Strategic Defence Review recommendation to increase the number of Active Reserves to increase by 20% when funding allows.
Asked by: Jodie Gosling (Labour - Nuneaton)
Question to the Ministry of Justice:
To ask the Secretary of State for Justice, whether he has made an assessment of the potential merits of introducing a permanent exemption to Jury service for people suffering from lifelong or degenerative conditions.
Answered by Sarah Sackman - Minister of State (Ministry of Justice)
The Government has not made a specific assessment of introducing a permanent exemption for people with lifelong or degenerative conditions. Jury service is an important civic duty, and the Government is committed to ensuring that disability is never a barrier to serving.
People with these conditions who feel unable to undertake jury service may apply to be excused, with each application considered carefully on a case-by-case basis.
Where a person wishes to serve, His Majesty’s Courts and Tribunals Service will make reasonable adjustments to accommodate their needs whenever possible, so they can participate fully at no personal cost.
Asked by: Jodie Gosling (Labour - Nuneaton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the planned timeline is for publishing the next iteration of the taxonomy being developed as part of the ongoing reforms to Drug Tariff Part IX.
Answered by Zubir Ahmed
The final draft, version 1.2, of the Part IX Drug Tariff (Med Tech in the community) Wave 1 categorisation was developed in collaboration with an Expert Reference Group and updated in line with stakeholder feedback over four iterations. The final version was published in October 2025 and can be found on the NHS Business Services Authority Website at the following link:
https://www.nhsbsa.nhs.uk/manufacturers-and-suppliers/drug-tariff-part-ix-information
The Department is currently recruiting Independent Assessment Panels (IAPs) for Wave 1 and has agreed to ask them to review late feedback received from a company on the eye drops category. This is due to take place in February 2026 and will not require further input from industry as it has already been circulated for comment by them.
The Department has also offered to review Drug Tariff Committee feedback regarding the categorisation of medical devices that fall into waves 2 to 4.
The categorisation for waves 2 and 3 is currently being reviewed, and the Department expects to share the updated versions in early 2026 well in advance of the projected launch of waves 2 and 3 in 2027 and 2028 respectively. There are no confirmed plans for reviewing wave 4 at this time. The earliest launch would be in January 2029. All dates are subject to the outcome of the review of wave one.
The Department recognises that the categorisation is not stagnant and may need further amendments as medical devices continue to evolve and the IAPs are stood up. Companies can suggest further amendments when they apply to Part IX of the Drug Tariff or through the Drug Tariff Committee.